secwatch.observer — SEC 8-K summary
======================================

Issuer:     Black Diamond Therapeutics, Inc. (BDTX)
CIK:        0001701541
Form:       8-K
Filed at:   2024-11-05T23:59:59+00:00
Accession:  0001701541-24-000040
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Black Diamond Therapeutics reports Q3 net loss of $15.6M; BDTX-1535 Phase 2 data
--------------------------------------------------------------------------------

- Net loss of $15.6M in Q3 2024 vs $23.0M in Q3 2023; cash and investments $112.7M, sufficient into Q2 2026.
- R&D expenses decreased to $12.9M from $16.2M YoY due to workforce efficiencies and reduced early discovery.
- Announced restructuring in Oct 2024 to prioritize BDTX-1535 and extend cash runway; deprioritized BDTX-4933.
- Initial Phase 2 data for BDTX-1535 in EGFRm NSCLC: 42% ORR in 19 patients with osimertinib resistance mutations; DOR ~8+ months in first 3 PRs.
- Expects to disclose initial Phase 2 data in first-line and updated recurrent setting data plus FDA feedback in Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701541/000170154124000040/0001701541-24-000040-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701541/000170154124000040/bdtx-20241105.htm
  HTML page:      https://secwatch.observer/filing/0001701541-24-000040

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer